Skip to main content

Table 6 APOE rs4420638 polymorphism and cardiometabolic risk

From: Association study of APOE gene polymorphisms with diabetes and the main cardiometabolic risk factors, in the Algerian population

rs4420638 Major allele/minor allele ISOR
   Genotypes (N)
p
OR [95% CI]
p
OR* [95% CI]
p
T2D A/G Control Case AG vs AA:
1.20 [0.65–2.22]
p = 0.56
0.99 [0.56–1.75]
p = 0.98
AA (515)
AG(124)
GG (9)
AA (63)
AG(16)
GG (0)
p = 0.56
Obesity A/G AA (463)
AG (128)
GG (10)
AA (136)
AG (21)
GG (0)
AG vs AA:
0.51 [0.30–0.85]
p = 0.01*
0.48[0.29–0.79]
p = 0.004*
p = 0.02
MetS A/G AA (473)
AG (118)
GG (7)
AA (117)
AG (27)
GG (3)
AG vs AA:
0.93 [0.57–1.53]
p = 0.78
GG vs AA:
3.19 [0.73–13.89]
p = 0.12
1.10 [0.71–1.70]
p = 0.66
p = 0.68
HBP A/G AA (469)
AG (128)
GG (7)
AA (20)
AG (127)
GG (3)
AG vs AA:
0.56 [0.33–0.96]
p = 0.03
GG vs AA:
2.24 [0.51–9.84]
p = 0.29
0.73 [0.47–1.14]
p = 0.17
p < 0.001   
  1. T2D type 2 diabetes, MetS metabolic syndrome, HBP high blood pressure. OR adjusted on age, gender, physical activity, and smoking status. OR* obtained for additive model. p values were adjusted for age, gender, physical activity, and smoking status. Significant p values are indicated in italics with an asterisk